Abemaciclib + Irinotecan + Temozolomide
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sarcoma, Ewing
Conditions
Sarcoma, Ewing, Neoplasm Metastasis
Trial Timeline
Sep 20, 2022 → Sep 1, 2028
NCT ID
NCT05440786About Abemaciclib + Irinotecan + Temozolomide
Abemaciclib + Irinotecan + Temozolomide is a phase 2 stage product being developed by Eli Lilly for Sarcoma, Ewing. The current trial status is active. This product is registered under clinical trial identifier NCT05440786. Target conditions include Sarcoma, Ewing, Neoplasm Metastasis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05440786 | Phase 2 | Active |
Competing Products
20 competing products in Sarcoma, Ewing